We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NAUT:NASDAQNautilus Biotechnology, Inc. Analysis

Data as of 2026-08-19 - not real-time

$0.85

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $0.8518, Nautilus Biotechnology, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Over a rolling month the price has lost 49.6%. Momentum indicators put RSI at 21.6 (oversold) with MACD reading bullish. Recent trading has carved out support near $0.8410 and resistance around $1.79.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 369.6% above the current quote.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 113.2%, a beta of 0.06 and a maximum drawdown of 78.4%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.

Top Market Events

SEATTLE, July 28, 2026 GLOBE NEWSWIRE -- Nautilus Biotechnology, Inc.Nautilus Biotechnology Inc NAUT leverages proteoform advancements and strategic collaborations to drive future growth...Seeking Alpha21dNautilus Biotechnology, Inc.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 21.6 signals oversold conditions
  • Trading below the 200-day average of 2.21

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 21.6 signals oversold conditions
  • Trading below the 200-day average of 2.21

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +369.6% versus the current price
  • Negative return on equity of -36.2%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-1.2
ROE-36.21%
ROA-20.83%
Debt/Equity21.21
P/B Ratio0.8
Op. Cash Flow$-50235000
Free Cash Flow$-29418376
Industry P/E30.3

Technical Analysis

TrendBearish
RSI21.6
Support$0.84
Resistance$1.79
MA 20$1.10
MA 50$1.64
MA 200$2.21
MACDBullish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Target Price$4.00
Upside/Downside369.59%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.06
Volatility113.21%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.